Novavax Covid-19 vaccine elicits immune response in early trial
A Covid-19 vaccine developed by US-based Novavax elicited robust antibody responses and appeared to be safe in a Phase-I human trial, the company has said.No serious adverse events were reported and safety follow-up continues, Novavax said…